

1 **Usability of three blood-based HIV self-testing devices among men who have**
2 **sex with men and female sex workers in Yaounde and Douala, Cameroon**

3 Awono Noah JP Yves^{1,6*}, Justin Ndié^{1,6}, Francis Ateba Ndongo^{1,8}, Onesimus Yongwa²,
4 Rogacien Kana^{1,6}, Martial Bonyohe¹, Plessy Hedgar Mboussam², Tatiana Palisson Avang¹,
5 Fatima Moulioum¹, Félicité Tabala Naah¹, Gutenberg Tchikangni², Audrey Djomo Nzaddi³,
6 Alice Ketchaji⁴, Carelle Djofang Yepndo⁴, Gildas Nguemkam¹, Charles Baudelaire Ndindjock
7 IV², Brice Seukam², Yagaï Bouba³, Ernest Désiré Mvilongo Anaba³, Rina Estelle Djoukwe⁵,
8 Serge Billong^{4,7}, Karin Hatzold¹⁰, Annie Michele Salla², Jérôme Ateudjieu^{1,9}, Anne Cécile
9 Zoung - Kanyi Bissek^{1,7}

10 ¹⁻ Operational Health Research Division/Ministry of Public Health, Cameroon

11 ²⁻ Cameroon Social Marketing Association, Cameroon

12 ³⁻ Central Technical Group/National AIDS Control Committee

13 ⁴⁻ Department of Disease Control, Epidemics and Pandemics/Ministry of Public Health

14 ⁵⁻ Directorate of Pharmacy, Medicines and Laboratories/Ministry of Public Health

15 ⁶⁻ Media Convergence Health Research Centre, Cameroon

16 ⁷⁻ University of Yaounde I, Faculty of Medicine and Biomedical Sciences, Cameroon

17 ⁸⁻ Faculty of Medicine, University of Garoua, Cameroon

18 ⁹⁻ Department of Public Health, University of Dschang, Cameroon

19 ¹⁰⁻ Population Services International

20 Corresponding author : Awono Noah Jean Pierre Yves ; Tel : +237 697641459

21 e.mail : anjpy@live.fr (ANJPY)

22 **Competing interests:** The authors have declared that no competing interests exist.

23

24

25

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 **Abstract**

27 **Background**

28 Blood-based HIV self-testing represents an alternative for increasing screening among key
29 populations or populations with difficult access. In Cameroon, very few studies, on the usability
30 of HIV self-tests based on blood samples, have been carried out among these groups.

31 **Objective**

32 The aim of this study was to assess the usability of blood-based HIV self-testing among men
33 who have sex with men (MSM) and female sex workers (FSWs) in the cities of Yaoundé and
34 Douala, Cameroon.

35 **Materials and Methods**

36 An observational study was conducted in 17 Community-Based Organisations (CBOs),
37 including 10 MSM and 07 FSWs in Yaoundé and Douala from 11 to 22 June 2022. The study
38 population consisted of HCV and MSM aged 21 years and over who agreed to participate in
39 the study. After they were recruited consecutively in their respective CBOs, they received
40 counselling, unassisted HIV blood self-testing and condoms. Data was collected using an
41 administered questionnaire. Three HIV blood self-testing devices were used in the study: Mylan
42 HIV Self-Test, Sure Check HIV Test® (Chembio Diagnostics Inc), Check Now HIV Self-
43 Test(Abbott™ Point Of Care). Analysis was conducted using SPSS 23 software with a 95%
44 confidence level.

45 **Results**

46 Of 817 participants who completed the HIV blood self-test, just over half were TS 459(56.2%);
47 the median age was 27 years (IQR: 22 years - 34 years) and the 25-49 age group was most
48 represented 482(59.0%). One participant in ten (10%) had never been tested for HIV. However,
49 98.6% of participants agreed to use the HIV blood self-test and the vast majority (97.1%)
50 followed the steps for carrying out the HIV blood self-test. An MSM was 4 times more likely

51 to pass an HIV blood self-test than a TS (aOR= 4.01; 95% CI: 1.181-13.625; p=0.026).
52 Similarly, TS and MSM who used the Abbott Check Now HIV Self-Test (aOR= 3.85; 95% CI:
53 1.246-11.908; p=0.019) and Chembio Sure Check HIV Test (aOR= 2.83; 95% CI: 1.072-7.720;
54 p=0.036) were respectively 3.8 and 2.8 times and more likely to pass their self-test than those
55 who used the Mylan blood self-test. Agreement between a participant's HIV blood self-test
56 result and Abbott-trained investigator-observers was moderate ($\kappa=0.485$; CI95% (0.359-0.610);
57 p=0.001) while agreement with Chembio and Mylan was respectively low ($\kappa=0.329$; CI95%
58 (0.203-0.454); p=0.001) and very low ($\kappa=0.194$; CI95%(0.05-0.329); p=0.001).

59 **Conclusion**

60 HIV blood self-testing is acceptable and usable by key populations in Cameroon. Although
61 usability was limited by problems in interpreting results and incorrect disposal of waste t by
62 key populations, a blood-based HIV Self-Test, with moderate concordance, proved suitable for
63 unassisted use in key populations, what could help improve HIV prevention interventions.

64 ***Introduction***

65 In every region of the world, key populations -men who have sex with men (MSM), female sex
66 workers (FSWs), drug users and transgender people- and their partners are much more affected
67 by HIV infection than the general population. In sub-Saharan Africa specifically, key
68 populations and their partners accounted for 51% of new HIV infections in 2021. Given the
69 importance of MSM and MSM-attached populations, where routine HIV screening strategies
70 have produced mixed results, the WHO recommends implementing new strategies such as HIV
71 self-testing (HIVST) [1]. Hence the prequalification of the first salivary HIV self-testing kit by
72 the WHO in 2017. The first HIV blood self-test was prequalified in 2019, followed by 4 other
73 blood self-tests between 2019 and 2022. In terms of institutional support, formal HIV self-
74 testing regulations have existed in many African countries since 2017, whereas they are still
75 being developed or even informal in other countries [2]. However, in sub-Saharan Africa, apart

76 from the Democratic Republic of the Congo (DRC), the Central African Republic (CAR) and
77 Benin, very few French-speaking countries have shown concern for blood-based HIV self-
78 testing. In the DRC, evidence has been produced in favour of the feasibility and performance
79 of blood self-testing in the general [3] and key populations such as FSWs [4] or vulnerable
80 populations such as adolescents [5]. In general, the majority of users were able to understand
81 the instructions for use, identify the different components of the self-test kit, perform the test
82 until a valid test was obtained, and good interpretation as well. Many of the advantages
83 highlighted by these studies, such as confidentiality, speed, and efficiency, were pointed out by
84 users, despite some difficulties encountered in using the lancet and misinterpreted results. These
85 studies suggest that blood self-testing could be considered as an additional self-testing option
86 for key populations. In Cameroon, in 2018, HIV prevalence in the general population (15-49
87 years) was estimated at a rate of 2.7% [6]. The percentage among MSM and FSWs was 20.6%
88 and 24.3% respectively [7]. In addition to the burden of HIV, these populations are afraid of
89 stigmatisation and discrimination as a result of taking part in conventional HIV screening
90 programmes. A study conducted in Douala-Cameroon, has shown that only 48% of MSM had
91 already been exposed to HIV prevention interventions [8]. Some research carried on the
92 acceptability of salivary HIV self-tests among MSM and FSWs in Yaoundé, has shown a high
93 level of acceptability and has led to the adoption of salivary HIV self-testing among MSM and
94 FSWs in Cameroon [9]. If blood-based HIV self-tests are to be introduced in this country as a
95 complement to the already-approved saliva self-test, there must first of all be evidence of their
96 usability. To date, no locally conducted and published study has shed any light on this strategic
97 option. To sum up, the aim of this study was to assess the usability of HIV self-testing among
98 men who have sex with men and female sex workers in Yaoundé and Douala. The study
99 included compliance with the steps involved in carrying out the HIV blood self-test and
100 interpreting the results.

101 **Methodology**

102 ***Ethical considerations***

103 This protocol obtained a favourable opinion from the National Ethics Committee for
104 Human Health Research of Cameroon (reference numbers 2022/04/1448/CE/CNERSH/SP) and
105 from the Operational Health Research Division of the Ministry of Health of Cameroon
106 (Administrative Research Authorisation reference numbers 031-16-22). A written informed
107 consent was obtained from all participants. All data collected was treated confidentially and
108 stored within the limits permitted by law.

109 ***Type of study***

110 A cross-sectional and observational study was conducted from 11 to 22 June 2022 in 17
111 community-based organisations (CBOs) in Yaoundé and Douala.

112 ***Selection of the study population***

113 The study population consisted of MSM and FSWs, aged 21 years and over, declaring unknown
114 HIV status or HIV-negative for more than three months, fluent in French and/or English and
115 usually receiving HIV testing services offered by CBOs involved in the implementation of HIV
116 control activities. Any participants who were on PrEP (pre-exposure prophylaxis) or
117 antiretroviral treatment, had a known HIV-positive status and/or had extenuating conditions
118 (e.g., acute illness) that might interfere with the study process were automatically excluded.

119 ***Site selection***

120 The study was carried out in Cameroon, a Central African country with a population of around
121 25 million. The study was conducted in the two major Cameroonian cities namely Yaoundé
122 (the capital city) and Douala (the economic capital). They were chosen because of the size of
123 their Community-Based Organisations (CBOs), key populations and their high "hot spot"
124 densities. In each study city, the CBOs were selected based on the size of the target effectively
125 covered and the acceptance of the study by their leaders.

126 ***Sample size and sampling.***

127 The sample size was calculated according to the criteria recommended by the WHO [10] taking
128 into account the proportion of HIV testing observed in each target group in previous national
129 or regional studies. The minimum sample size adjusted for the 15% non-response rate was
130 estimated at 785 study participants (423 TS and 362 MSM), including 262 for each HIV self-
131 testing device.

132 ***Recruitment of MSM and sex workers***

133 MSM were recruited by leader mothers, innkeepers, and gatekeepers in the community and in
134 the hot spots. They were recruited consecutively until the planned sample size for each type of
135 HIV blood self-test was reached. MSM were mobilised by peer educators and community leader
136 fathers. They were also recruited consecutively until the planned sample size for each type of
137 HIV blood self-test was reached.

138 ***Data collection***

139 Data collection was carried out by a research team consisting of twenty healthcare staff who
140 had been trained to perform blood self-tests (laboratory technicians and nurses). The study ran
141 for 9 months from November 2021 to July 2022 and included eight (08) days of data collection
142 from 11 to 22 June 2022. In each CBO selected for the survey, a setting was set up to conduct
143 the data collection and HIV blood self-test procedures in complete confidentiality. To begin
144 with, data collectors introduced themselves to every participant. After that authorisations for
145 the study were distributed and its purpose highlighted. Then, participants were given an
146 information leaflet and their informed consent was obtained. Information about their eligibility
147 for the study was also collected. Next, the blood self-test kit was given to the recruited
148 participant to carry out the blood self-test procedure under observation. The tests were done on
149 site and the results were reported by participants and two trained investigator-observers in a
150 row. CBO managers and staff provided pre- and post-test counselling to each participant. Once
151 the self-testing process was complete, every investigator-observer carried on with the
152 administration of the questionnaire to one participant at a time. As there were no available

153 standardised questionnaires about the usability of HIV blood self-tests at the time of the study,
154 a product-specific semi-structured questionnaire was developed (Text S1) based on WHO
155 documentation on prequalification [11-13]. The questionnaire was tested with a sample of 43
156 participants (19 MSM and 24 FSWs) for each HIV self-test that had to be used. A semi-
157 structured questionnaire, set up on the tablets via the Kobo Collect application, was
158 administered by observers. The questionnaire included an observation checklist of the HIV self-
159 testing process, test results, waste management and participants' experiences with the device
160 and instructions for use. The observer systematically provided post-test counselling and
161 condoms to study participants after they had completed the test and read the results.
162 MSM/FSWs with a reactive test were referred to their CBO's supervising health facility for
163 confirmation of their test result in accordance with the national algorithm for HIV testing and
164 management where appropriate.

165 ***Type of blood-based Self-test devices***

166 Three blood-based HIV Self-Testing (HIVST) devices were used in the study: Mylan® HIV
167 Self-Test (Atomo Diagnostics Pvt. Ltd), Sure Check® HIV Self-Test (Chembio Diagnostic
168 Systems, Inc), Check Now™ HIV Self-Test (Abbott Rapid Diagnostics Jena GmbH). Each HIV
169 Self-Test device included the manufacturer's instructions for use and other kit components. No
170 additional user aids, demonstrations or assistance were provided to participants.

171 **Data processing and statistical analysis**

172 After data was collected with the KoboCollect application deployed through the KoboToolbox
173 platform, it was imported into SPSS (version 23) for analysis using descriptive statistics and
174 multivariate regression models. For this study, usability of the blood self-test was defined as
175 the proportion of MSM/STDs who were able to perform self-testing steps, interpret the result
176 and dispose of the waste in exact compliance with the manufacturer's instructions. Variables
177 that were statistically significant (p-value <0.05) in the univariate analysis were included in the
178 multivariate logistic regression. Multivariate logistic regression analysis was used to identify

179 factors associated with successful self-testing. The results of the analysis are presented as
180 adjusted odds ratios (aOR) with 95% confidence intervals (CI) and interpreted as the odds of
181 successful completion of the self-test among non-professional users who have been exposed or
182 not to the associated factor. Variables included in the multivariable logistic regression analysis
183 were city, type of key population, age, sex, education, employment, living status, ever HIV
184 tested, and type of blood based HIVST kit. Self-test success or self-test usability was calculated
185 as the percentage of participants who correctly performed the key steps and obtained an
186 interpretable result. Tests that did not produce a control line were identified as "Invalid" and
187 reported as a failure.

188 Agreement between reactive (positive) and non-reactive (negative) HIV self-test results was
189 measured using Cohen's Kappa based on agreement rates between reactive and non-reactive
190 self-test results interpreted by study participants and observing healthcare staff. This analysis
191 excluded incomplete self-tests, invalid results interpreted by healthcare staff and inconclusive
192 (uncertain) results interpreted by study participants.

193 **Results**

194 *Demographic characteristics and HIV testing history of MSM and* 195 *FSW*

196 Of the 817 participants who agreed to be tested for HIV, 56.3% were living in the city of
197 Douala; almost all of them were Cameroonian (98.2%); 56.2% were MSM; the median age
198 was 27 years and the 25-49 age group was the most represented (59%); the majority of
199 participants had completed secondary education (58.8%); the unemployed accounted for just
200 under half of the sample (43.3%); the vast majority of participants were single (77.8%); one in
201 ten participants (10%) had never been tested for HIV before the test was carried out as part of
202 this study. A wide disparity between the two sub-populations was observed (17.9% of MSM

203 compared with 3.9% of MSM). 280 Chembio Sure Check HIV Test®, 272 Abbott™Check
204 Now HIV Self-Test and 265 Mylan® HIV Self-Test were used for this study (Table 1).

205 **Table I** : Distribution of TS and MSM according to sociodemographic characteristics and
206 HIV testing history.

Characteristics	Chembio Sure Check HIV Test®	Abbott™ Check Now HIV Self-Test	Mylan® HIV Self-Test	Total	
	n=280 n(%)	n=272 n(%)	n=265 n(%)	n=817 n(%)	
City					
	<i>Yaoundé</i>	120(42.9)	118(43.4)	117(44.2)	355(43.5)
	<i>Douala</i>	160(57.1)	154(56.6)	148(55.8)	462(56.5)
Nationality					
	<i>Foreign</i>	6(2.1)	2(0.7)	7(2.6)	15(1.8)
	<i>Cameroonian</i>	274(97.9)	270(99.3)	258(97.4)	802(98.2)
Population type					
	<i>SW</i>	157(56.1)	127(46.7)	175(66.0)	459(56.2)
	<i>MSM</i>	123(43.9)	145(53.3)	90(34.0)	358(43.8)
Age (in years)					
	Median (IQR)	26.0(22-34)	26.5(22-32)	27.0(23-34)	27.0(22-34)
	<i>21-24</i>	118(42.1)	115(42.3)	85(32.1)	318(38.9)
	<i>25-49</i>	156(55.7)	153(56.3)	173(65.3)	482(59.0)
	<i>50+</i>	6(2.1)	4(1.5)	7(2.6)	17(2.1)
Education					
	<i>Elementary and under</i>	15(5.4)	10(3.7)	17(6.4)	42(5.1)
	<i>Second level</i>	162(57.9)	167(61.4)	151(57.0)	480(58.8)
	<i>Advanced</i>	103(36.8)	95(34.9)	97(36.6)	295(36.1)
Employment status					
	<i>Self-employed</i>	93(33.2)	88(32.4)	97(36.6)	278(34.0)
	<i>Unemployed</i>	124(44.3)	112(41.2)	118(44.5)	354(43.3)
	<i>Employed in private sector</i>	55(19.6)	67(24.6)	45(17.0)	167(20.4)
	<i>Employed in public sector</i>	8(2.9)	5(1.8)	5(1.9)	18(2.2)
Marital status					
	<i>Single</i>	216(77.1)	213(78.3)	206(78.0)	635(77.8)
	<i>Divorced</i>	11(3.9)	5(1.8)	9(3.4)	25(3.1)
	<i>Widowed</i>	3(1.1)	1(0.4)	4(1.5)	8(1.0)
	<i>Cohabiting</i>	28(10.0)	34(12.5)	32(12.1)	94(11.5)
	<i>Married</i>	22(7.9)	19(7.0)	13(4.9)	54(6.6)
History of HIV testing					
	<i>Yes</i>	255(91.1)	239(87.9)	241(90.9)	735(90.0)
	<i>No</i>	25(8.9)	33(12.1)	24(9.1)	82(10.0)

207 Usability of the HIV blood self-test by study participants

208 The vast majority of participants (97.1%) followed the steps for performing the self-test; the
209 errors commonly made while using the self-test were, in order of occurrence: incorrect volume
210 of blood drawn (87.9%); insufficient collection/addition of blood to the well (29.9%),
211 particularly with Chembio (39.3%) and Mylan (37.4%); failure to dispose of waste according
212 to the leaflet (23.4%), particularly with Chembio (24.3%) and Mylan (27.5%); incorrect

213 positioning of the self-test device (20.4%), particularly with Chembio (22.9%) and Mylan
 214 (28.7%) (Table 2).

215 **Table II** : Ability to perform HIV self-testing in exact compliance with the leaflet

Characteristics	Chembio® <i>Sure Check HIV Self-Test</i>	Abbott™ <i>Check Now HIV Self-Test</i>	<i>Mylan® HIV Self-Test</i>	Total
	n=279 n(%)	n=272 n(%)	n=263 n(%)	n=814 n(%)
Completeness of self-test steps				
<i>Success</i>	273(97.8)	268(98.5)	249(94.7)	790(97.1)
<i>Failure</i>	6(2.2)	4(1.5)	14(5.3)	24(2.9)
Frequent errors made during self-testing process				
<i>Incorrect volume of blood drawn (tube over/underfilled)</i>	246(91.1)	226(86.9)	217(85.4)	689(87.9)
<i>Insufficient blood collected/added to the well</i>	110(39.3)	32(11.8)	99(37.4)	241(29.5)
<i>Waste not disposed of in accordance with instructions</i>	68(24.3)	50(18.4)	73(27.5)	191(23.4)
<i>Incorrect positioning of the device</i>	64(22.9)	27(9.9)	76(28.7)	167(20.4)

216
 217 Regarding agreement in the interpretation of results between participants and the healthcare
 218 workers trained as HIV testing counsellors, overall, the percentage of positive agreement was
 219 90.9% and the percentage of negative agreement was 81.7%. The total percentage of agreement
 220 was 82.3%. However, when controlling the random effect, this total percentage of agreement
 221 dropped to 35.1%, indicating low overall agreement ($\kappa=0.351$; 95% CI (0.274-0.427);
 222 $P=0.001$). Notwithstanding, disparities were identified depending on the blood self-test device
 223 used. Indeed, agreement between a participant's (MSM or TS) HIV blood self-test result and
 224 investigator-observers trained with **Abbott™ Check Now HIV Self-Test** was moderate
 225 ($\kappa=0.485$; 95% CI (0.359-0.610); $P=0.001$) while agreement with **Chembio Sure Check HIV**
 226 **Test®** and **Mylan® HIV Self-Test** was respectively low ($\kappa=0.329$; 95% CI (0.203-0.454);
 227 $P=0.001$) and very low ($\kappa=0.194$; 95% CI (0.05-0.329); $P=0.001$) with percentages of total
 228 agreement corrected by the random effect of 32.9% and 19.4% (Table 3).

229 **Table III:** Agreement between HIV blood self-test results interpreted respectively by
 230 participants trained health workers

Characteristics	Chembio		Abbott™		Mylan® HIV Self-Test	Total
	Sure Check HIV Test®	Check Now HIV Self-Test	Check Now HIV Self-Test	Check Now HIV Self-Test		
	n=269	n=263	n=244	n=776		
Interpreted self-test results						
<i>Positive agreement</i>	17	25	8	50		
<i>Negative agreement</i>	201	198	190	589		
<i>Positive disagreement</i>	1	0	4	5		
<i>Negative disagreement</i>	50	40	42	132		
Percentage of agreement						
<i>Ppositive agreement percentage</i>	94.4%	100%	66.7%	90.9%		
<i>Negative agreement percentage</i>	80.1%	83.2%	81.9%	81.7%		
<i>Total agreement percentage</i>	81%	84.8%	81.1%	82.3%		
Cohen's Kappa (κ)	0.329	0.485	0.194	0.351		
95% CI of Cohen's Kappa (lb - ub)	(0.203-0.454)	(0.359-0.610)	(0.05-0.329)	(0.274-0.427)		
P	0.001*	0.001*	0.001*	0.001*		

231 **P:** significance level; *: <0.01; **CI (95%):** 95% confidence interval; **lb** : lower bound; **ub**: upper bound

232 **Factors associated with successful HIV blood self-testing**

233 Multivariate logistic regression analysis (Table 4) showed a significant positive association
 234 between successful self-testing with Abbott Check Now HIV Self-Test (aOR= 3.85; 95% CI:
 235 1.246-11.908; p=0.019), Chembio Sure Check HIV Test (aOR= 2.83; 95% CI: 1.072-7.720;
 236 p=0.036) and being MSM (aOR= 4.01; 95% CI: 1.181-13.625; p=0.026). Multivariable analysis
 237 also confirmed a significant negative association between self-test success and the city of
 238 residence (aOR = 0.27; 95% CI: 0.110-0.676). Age over 30 years, which was nearly negatively
 239 associated with successful self-testing in the univariate analysis, was not confirmed in the
 240 multivariate analysis after adjustment with other variables. In fact, MSM were 4 times more
 241 likely to succeed in self-testing than an FSW. Similarly, FSW and MSM who used the Abbott
 242 and Chembio blood self-test were respectively 3.8 and 2.8 times more likely to pass their test
 243 than those who used the Mylan blood self-test. In addition, the probability of carrying out their
 244 blood self-test successfully was 73% lower for participants living in the city of Yaoundé than
 245 for those living in the city of Douala.

246 **Table IV:** Factors associated with successful completion of all stages of blood self-testing

	N	Univariable analysis of self-test success			Multivariable analysis of self-test success				N2
		n(%)	B(SE)	P	OR(IC95%)	B(SE)	P	aOR (IC95%)	
City									814
<i>Douala</i>	462	454(98.3)			1			1	
<i>Yaoundé</i>	355	337(94.9)	-1.109**(0.431)	0.01	0.33(0.142-0.768)	-1.300*(0.463)	0.005	0.27(0.110-0.676)	
Type of population									
<i>FSWs</i>	459	437(95.2)			1			1	
<i>MSM</i>	358	354(98.9)	1.494*(0.548)	0.006	4.45(1.521-13.048)	1.389*(0.624)	0.026	4.01(1.181-13.625)	
Age									
<i>Under 25</i>	318	312(98.1)			1			1	
<i>25 to 30 years old</i>	232	225(97.0)	-0.481(0.563)	0.393	0.61(0.205-1.864)	-0.179(0.605)	0.768	0.83(0.255-2.739)	
<i>Over 30</i>	267	254(95.1)	-0.979(0.501)	0.051	0.34(0.117-0.972)	-0.540(0.551)	0.326	0.58(0.198-1.714)	
Education									
<i>High school or less</i>	664	641(96.5)			1			1	
<i>Advanced</i>	153	150(98.0)	0.584(0.621)	0.346	1.79(0.532-6.054)	0.161(0.668)	0.809	1.17(0.317-4.353)	
Employment status									
<i>Unemployed</i>	353	342(96.9)			1			1	
<i>Employed</i>	463	448(96.8)	-0.040(0.403)	0.921	0.96(0.436-2.118)	-0.250(0.432)	0.562	0.77(0.334-1.814)	
Living status									
<i>Living alone</i>	668	650(97.3)			1			1	
<i>Living with a partner</i>	148	140(94.6)	-0.724 (0.435)	0.096	0.48(0.207-1.137)	-0.239(0.468)	0.610	0.78(0.314-1.971)	
Has already been tested for HIV									
<i>No</i>	81	79(97.5)			1			1	
<i>Yes</i>	735	711(96.7)	-0.288(0.745)	0.700	0.75(0.174-3.233)	0.375(0.815)	0.646	1.45(0.295-7.180)	
Type of Self Testing device									
<i>Mylan</i>	265	249(94.0)			1			1	
<i>Chembio</i>	280	274(97.9)	1.077**(0.487)	0.027	2.93(1.131-7.617)	1.044**(0.497)	0.036	2.83(1.072-7.520)	
<i>Abbott</i>	272	268(98.5)	1.460**(0.574)	0.010	4.30(1.420-13.053)	1.349**(0.576)	0.019	3.85(1.246-11.908)	

247 N: total number of subjects in univariate analysis; n: number of subjects in category; %: percentage; B: regression coefficient; SE: standard error; P: significance level; *: <0.01;

248 **: <0.05; OR: Crude Odds Ratio; aOR: adjusted Odds Ratio; 95% CI: 95% confidence interval for the Odds Ratio; N2: total number of subjects in multivariate analysis

249 Discussion

250 The HIV epidemic in Cameroon is widespread among key populations such as sex workers and
251 men who have sex with men, with national prevalence rates of 5.6% and 10.4% respectively.
252 The Cameroon government is committed to achieving the UNAIDS 95-95-95 targets and to
253 putting an end to AIDS by 2030. Innovations in HIV testing, namely testing by a non-
254 professional provider and self-testing, have been implemented in Cameroon since 2015 (when
255 community-based testing was validated by CBOs) and 2022, respectively, with the aim of
256 increasing access to routine services for people who have not been reached yet. Available data
257 in Cameroon shows that these screening innovations are effective in reaching undiagnosed
258 people, those getting screened for the first time or those who would not like to get screened or
259 come to health facilities as well (Spectrum programmatic data). The aim of this study was to
260 assess whether blood-based HIV testing kits could be used appropriately by unassisted non-
261 professionals in a context of low HIV prevalence in Cameroon. The ease of use of blood-based
262 HIV tests by non-professional users raised concerns about the potentially infectious nature of
263 waste from the procedure compared with oral fluid-based HIV self-tests. The results of this
264 study confirmed that unassisted blood-based HIV self-testing was perfectly feasible and that
265 the success of self-testing was significantly associated with the fact of being MSM and with
266 brand too. Indeed, the Abbott self-test had a 223% and MSM a 491% greater chance of passing
267 the steps involved in carrying out the test, compared with Mylan and FSWs respectively. In the
268 same vein, these results are similar to those of previous studies on HIV blood screening kits
269 conducted in the Democratic Republic of the Congo, Thailand, Central African Republic and
270 South Africa and Canada [3, 5, 14-16]. The study showed no association with employment
271 status unlike Bao, Majam, Green, Tran, Hung, Anh Luong Que et al.[17] who found an inverse
272 association between the type of self-test and self-test success. The proportion of MSM who had
273 never been tested for HIV prior to this study was 17.9%, which is more than three times higher
274 than that found among MSM in Nairobi [18] but half lower than that found in Canada among

275 student population [19]. Despite the feasibility of blood-based HIV self-tests, the study revealed
276 errors in the process of obtaining the blood sample or transferring it to the test well, failure to
277 dispose of waste according to the instructions, and incorrect positioning of the device; these
278 errors suggest the need to modify current rules so as to make the use of self-tests easier and
279 easier. These findings confirm those of previous studies in which most errors occurred during
280 the sample collection stage by users of finger-prick HIV tests [15-17, 19]. It is worth mentioning
281 that Abbott recorded the fewest errors. It was also found that the correct interpretation of HIV
282 self-test blood test results by non-professional users was, based on the 95% confidence intervals
283 of Cohen's Kappa statistic, very low to low, low to moderate and moderate to high for Mylan,
284 Chembio and Abbott respectively, compared with interpretation by trained healthcare staff.
285 This suggests that Abbott is probably appropriate for use in key populations on an unassisted
286 basis. Difficulties in interpreting results have also been reported in the literature, with
287 differences between the different approaches [3-5, 14,20]. A systematic review reported that in
288 studies using the unassisted approach, reactive results were often misinterpreted as non-reactive
289 [20]. Misinterpretation of positive results could have a negative impact on the control of the
290 HIV epidemic [21], as HIV self-testing is considered a triage test [1, 22].

291 **Conclusion**

292 This study showed a high level of usability (98%) of HIV blood self-tests among key
293 populations (MSM and FSWs) in the cities of Yaoundé and Douala. Despite the fact that
294 usability was restricted by results related issues and inappropriacy of waste disposal by key
295 populations, the Abbott blood self-test, with a moderate agreement, proved suitable for
296 unassisted use in key populations. These results are essential as they could help promote the
297 spread of blood-based HIV testing in addition to oral fluid-based HIV testing so as to offer a
298 greater choice of products to potential testees, thereby increasing uptake of HIV testing and
299 access to essential HIV prevention such as pre-exposure prophylaxis (PrEP) and treatment
300 services. The COVID-19 pandemic has made access to a range of affordable blood- and oral
301 fluid-based HIV tests more crucial than ever. Given the fact that restrictions are gradually lifted
302 and people are more and more getting access to safe and personal care, HIV self-tests are an

303 essential tool for accelerating catch-up HIV testing among the plethora of people who have not
304 benefited from it yet.

305 **Acknowledgments**

306 We are grateful to all the study participants for their contributions. We would also like to
307 express our gratitude to Mohammed Majam, for his collaboration and commitment in
308 implementing the study. We also thank Cameroon's Ministry of Public Health (MoPH),
309 Population Service International (PSI) - STAR Project and Cameroon Social Marketing
310 Association, Cameroon (ACMS) for providing the necessary and accurate resources.

311 **References**

- 312 [1] OMS. Lignes directrices sur l'autodépistage du VIH et la notification aux partenaires :
313 supplément aux lignes directrices unifiées sur les services de dépistage du VIH [Guidelines on
314 HIV selftesting and partner notification: supplement to consolidated guidelines on HIV testing
315 services]. 2018. Genève. <https://creativecommons.org/licenses/by-nc-sa/3.0/igo/>
- 316 [2] World Health Organization & UNITAID. Technology Landscape, HIV rapid diagnostic
317 tests for self-testing, December 2016, Semi-annual update. Geneva : WHO & UNITAID, 2016.
318 <http://www.who.int/hiv/pub/vct/hiv-self-testing-2016-december-edition/en/> (last access March
319 2017).
- 320 [3] Grésenguet G, Longo JD, Tonen-Wolyec S, Mboumba Bouassa RS, Belec L. Acceptability
321 and Usability Evaluation of Finger-Stick Whole Blood HIV Self-Test as An HIV Screening
322 Tool Adapted to The General Public in The Central African Republic. *Open AIDS J.* 2017;
323 11:101-118
- 324 [4] Tonen-Wolyec S, Batina-Agasa S, Longo JDD, Mboumba Bouassa RS, Bélec L. Insucient
325 education is a key factor of incorrect interpretation of HIV self-test results by female sex
326 workers in Democratic Republic of the Congo: a multicenter cross-sectional study. *Medicine.*
327 2019 Feb;98(6):e14218.
- 328 [5] Tonen-Wolyec S, Batina-Agasa S, Muwonga J, Mboumba Bouassa R-S, Kayembe
329 Tshilumba C, Bélec L. Acceptability, feasibility, and individual preferences of blood based HIV
330 self-testing in a population-based sample of adolescents in Kisangani, Democratic Republic of
331 the Congo. *PLoS One.* e0218795;14(7).

- 332 [6] Institut National de la Statistique et ICF International. Rapport de l'Enquête Démographique
333 et de Santé et à indicateurs multiples du Cameroun 2016. 2018. Calverton, Maryland, USA :
334 INS et ICF International <https://dhsprogram.com/pubs/pdf/fr260/fr260.pdf>
- 335 [7] Comité National de lutte contre le SIDA. (2017); 2016 Integrated Biological and Behavioral
336 Survey (IBBS) Report among Key Populations in Cameroon : Female sex workers and men
337 who have sex with men
- 338 [8] Holland CE, Papworth E, Billong SC, Kassegne S, Petitbon F, Mondoleba V, et al. (2015)
339 Access to HIV Services at Non-Governmental and Community-Based Organizations among
340 Men Who Have Sex with Men (MSM) in Cameroon: An Integrated Biological and Behavioral
341 Surveillance Analysis. PLoS ONE 10(4): e0122881.
342 <https://doi.org/10.1371/journal.pone.0122881>
- 343 [9] Billong SC , Eyebe S, Mossus T, Njindam Mfochive I, Tamoufe U, Fako G, Baral S, Zoung-
344 Kanyi AC, Kamgno J. Feasibility of demedicalization of HIV diagnosis in Cameroon:
345 experimentation with HIV self-test in "key populations". Health Sci. Dis: Vol 22 (2) February
346 2021 pp 23-27
- 347 [10] Stanley Lemeshow S, Hosmer DW Jr, Klar J and Lwanga SJ. Adequacy of Sample Size in
348 Health Studies. WHO, published by John Wiley & sons, 1991
- 349 [11] WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT Product: CheckNOW
350 HIV SELF TEST WHO reference number: PQDx 0481-032-00. 2022. available on
351 [https://extranet.who.int/pqweb/WHOPR/public-report-checknow-hiv-self-testpqdx-0481-032-](https://extranet.who.int/pqweb/WHOPR/public-report-checknow-hiv-self-testpqdx-0481-032-00)
352 [00](https://extranet.who.int/pqweb/WHOPR/public-report-checknow-hiv-self-testpqdx-0481-032-00)
- 353 [12] WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT Product: SURE CHECK
354 HIV SELF TEST WHO reference number: PQDx 0054-006-01. 2019. available on
355 [https://extranet.who.int/pqweb/content/public-report-sure-check-hiv-self-testpqdx-0054-006-](https://extranet.who.int/pqweb/content/public-report-sure-check-hiv-self-testpqdx-0054-006-01)
356 [01](https://extranet.who.int/pqweb/content/public-report-sure-check-hiv-self-testpqdx-0054-006-01)
- 357 [13] WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT Product: MYLAN HIV
358 SELF TEST WHO reference number: PQDx 0320-090-00. 2019. available on
359 <https://extranet.who.int/pqweb/content/public-report-mylan-hiv-self-testpqdx-0320-090-00>
- 360 [14] Tonen-Wolyec S, Tshilumba CK, Batina-Agasa S, Djang'eing'a RM, Hayette MP, Bélec
361 L. Comparison of practicability and effectiveness between unassisted HIV self-testing and
362 directly assisted HIV self-testing in the Democratic Republic of the Congo: a randomized
363 feasibility trial. BMC Infect Dis. 2020 Nov 11;20(1):830. pmid:3317670
- 364 [15] Smith P, Wallace M, Bekker LG. Adolescents' experience of a rapid HIV self-testing
365 device in youth-friendly clinic settings in Cape Town South Africa: a cross-sectional
366 community based usability study. Journal of the International AIDS Society 2016, 19:21111|
367 <http://dx.doi.org/10.7448/IAS.19.1.21111>

- 368 [16] Galli RA, Tian JMLH, Sumner-Williams M, McBain K, Stanizai E, Tharao W, et al. An
369 observed, prospective field study to evaluate the performance and acceptance of a blood-based
370 HIV self-test in Canada. *BMC Public Health*. 2021;21:1421. [https://doi.org/10.1186/s12889-](https://doi.org/10.1186/s12889-021-11418-z)
371 [021-11418-z](https://doi.org/10.1186/s12889-021-11418-z). [pmid:34275450](https://pubmed.ncbi.nlm.nih.gov/34275450/)
- 372 [17] Ngoc BV, Majam M, Green K, Tran T, Hung MT, Que AL, et al. (2023) Acceptability,
373 feasibility, and accuracy of blood-based HIV self-testing: A cross-sectional study in Ho Chi
374 Minh City, Vietnam. *PLOS Glob Public Health*. 2023 3(2): e0001438.
375 <https://doi.org/10.1371/journal.pgph.0001438>
- 376 [18] Ndungu K, Gichangi P, Temmerman M (2023) Evaluation of factors associated with HIV
377 self-testing Acceptability and Uptake among the MSM community in Nairobi, Kenya: A cross
378 sectional study. *PLoS ONE* 18(3): e0280540. <https://doi.org/10.1371/journal.pone.0280540>
- 379 [19] Pant Pai, N., Bhargava, M., Joseph, L., Sharma, J., Pillay, S., Balram, B., & Tellier, P.-P.
380 (2014). *Will an Unsupervised Self-Testing Strategy Be Feasible to Operationalize in Canada?*
381 *Results from a Pilot Study in Students of a Large Canadian University. AIDS Research and*
382 *Treatment, 2014, 1–8.* doi:10.1155/2014/747619
- 383 [20] Figueroa C, Johnson C, Ford N, Sands A, Dalal S, Meurant R, et al. Reliability of HIV
384 rapid diagnostic tests for self-testing performed by self-testers compared to health-care workers:
385 a systematic review and meta-analysis. *Lancet HIV*. 2018; 5(6):e277-e290.
- 386 [21] Prazuck, Karon, Gubavu, Andre, Legall, Bouvet, et al. A finger-stick whole-blood HIV
387 self test as an HIV screening tool adapted to the general public. *PloS One*. 2016;
388 11(2):e0146755.
- 389 [22] World Health Organization [WHO]. HIV Self-Testing Strategic Framework: A Guide For
390 Planning, Introducing And Scaling Up HIV Testing Services. Geneva 2018.